tradingkey.logo
tradingkey.logo
Search

ABVC Biopharma Inc

ABVC
Add to Watchlist
1.140USD
-0.020-1.72%
Close 09-23 16:00ET
29.64MMarket Cap
LossP/E TTM

About ABVC Biopharma Inc Company

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing products and technologies to combat various diseases. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It also focuses on the development of new drugs and medical devices derived from plants.

ABVC Biopharma Inc Profile

Ticker SymbolABVC
Company nameABVC Biopharma Inc
IPO dateNov 09, 2004
CEOPatil (Uttam Yashwant)
Number of employees16
Security typeOrdinary Share
Fiscal year-endNov 09
Address44370 Old Warm Springs Blvd
CityFREMONT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94538-6148
Phone15106680881
Websitehttps://abvcpharma.com/
Ticker SymbolABVC
IPO dateNov 09, 2004
CEOPatil (Uttam Yashwant)

Company Executives of ABVC Biopharma Inc

Name
Name/Position
Position
Shareholding
Change
Ms. Shuling Jiang
Ms. Shuling Jiang
Director
Director
3.07M
--
Ms. Shuling Jiang
Ms. Shuling Jiang
Director
Director
3.07M
--
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Chief Scientific Officer, Chief Strategy Officer, Director
Chief Scientific Officer, Chief Strategy Officer, Director
375.99K
--
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Chief Scientific Officer, Chief Strategy Officer, Director
Chief Scientific Officer, Chief Strategy Officer, Director
375.99K
--
Mr. Eugene Jiang
Mr. Eugene Jiang
Chairman of the Board, Chief Business Officer
Chairman of the Board, Chief Business Officer
126.64K
--
Mr. Eugene Jiang
Mr. Eugene Jiang
Chairman of the Board, Chief Business Officer
Chairman of the Board, Chief Business Officer
126.64K
--
Mr. Yoshinobu Odaira
Mr. Yoshinobu Odaira
Independent Director
Independent Director
57.76K
--
Mr. Yoshinobu Odaira
Mr. Yoshinobu Odaira
Independent Director
Independent Director
57.76K
--
Dr. Tsang Ming Jiang, Ph.D.
Dr. Tsang Ming Jiang, Ph.D.
Director
Director
41.99K
--
Dr. Tsang Ming Jiang, Ph.D.
Dr. Tsang Ming Jiang, Ph.D.
Director
Director
41.99K
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Shuling Jiang
Ms. Shuling Jiang
Director
Director
3.07M
--
Ms. Shuling Jiang
Ms. Shuling Jiang
Director
Director
3.07M
--
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Chief Scientific Officer, Chief Strategy Officer, Director
Chief Scientific Officer, Chief Strategy Officer, Director
375.99K
--
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Dr. Tsung-Shann (T.S.) Jiang, Ph.D.
Chief Scientific Officer, Chief Strategy Officer, Director
Chief Scientific Officer, Chief Strategy Officer, Director
375.99K
--
Mr. Eugene Jiang
Mr. Eugene Jiang
Chairman of the Board, Chief Business Officer
Chairman of the Board, Chief Business Officer
126.64K
--
Mr. Eugene Jiang
Mr. Eugene Jiang
Chairman of the Board, Chief Business Officer
Chairman of the Board, Chief Business Officer
126.64K
--

FAQs

Who are the top five shareholders of ABVC Biopharma Inc?

The top five shareholders of ABVC Biopharma Inc are: Ms. Shuling Jiang

How many institutions hold shares of ABVC Biopharma Inc (ABVC)?

As of 2026Q1, 27 institutions hold shares of ABVC Biopharma Inc, with a combined market value of approximately 866.42K, accounting for 3.41% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -376527.00.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.